SPARC - FOA Priorities

This webpage serves as the official list of Priorities for RFA-RM-17-009. This FOA provides application submission instructions, as well as guidance and restrictions on applicable tools and technologies.

Priorities for any specific receipt date will be finalized two months prior to the date. Preliminary Priorities may be listed sooner. All Priorities for a specific receipt date are of equal interest (i.e. the Priorities are not prioritized). The headings (e.g., "Interfacing priorities") are not Priorities; they are a means to categorize the Priorities. Priorities are listed under the headings.

On the cover page of your application, please list only the most relevant Priority. Listing more than one does not improve your chances of being invited to submit an OT2 application. If your concept does not align well with any one Priority, it may not be a good fit for this receipt date.

Priorities for the next available receipt date (applications November 1, 2017) 
Notional Priorities for future receipt dates (applications due February 1, 2018 and later) 
Archived Priorities from previous receipt dates

If you have any questions, or if you have suggestions for future Priorities, please email SPARC_NextGen-Tools@mail.nih.gov

 

Priorities for the November 1, 2017 receipt date (final)
This is the next available receipt date

  • Services provided to all SPARC consortium members:

NOTE: Service projects should propose a nominal task and an annual budget to provide community engagement and to develop task orders in response to SPARC consortium members' needs. If awarded, the nominal Other Transaction Award would be modified to provide funds for each new sub-project/task.

Provide a detailed description of your capabilities and turn-around times. These capabilities should be "turn-key" or nearly so. Applicants teams should include named key individuals who are familiar with the needs of the PNS neuromodulation community. Applicants are encouraged to identify the SPARC-funded "customers" who may need their service.

  • Large-scale high-resolution image capture of ex vivo specimens (e.g. TEM, X-ray, or light sheet)
  • Device testing (e.g., mechanical, electrochemical, toxicity, accelerated life, ISO 10993 or equivalent)
  • ASIC design, development, and validation
  • Packaging and encapsulation, or interconnects suitable for >6 month animal trials or human use
  • Genetics services (e.g., RNA-seq, viral vector development, and transgenic line generation)
  • Distribution of existing neuromodulation systems to the SPARC consortium. While some adaptation may be required to build interfaces for SPARC1 or SPARC3 investigators, the emphasis of this priority is on the manufacture, distribution, training, and support for these technologies and the associated surgical methods to implant them in nerves, ganglia, or plexi 
  • Animal and tissue preparation priorities:
    • Genetic approaches for large animals to facilitate imaging/targeting or interfacing with peripheral nerves and/or end organs (e.g., transgenic models, viral vectors, etc.)
    • Methods for accessing and patch clamping ganglia, plexi, and small nerves. This may include techniques for enzymatic digestion or robotic automation of access to dissociated ganglia
    • Optimization of techniques to label human peripheral nerves and/or end organs. This may include new fluorophores or image processing algorithms to improve immunohistochemical analysis of small nerves or nerve-organ junctions
  • Imaging and targeting priorities:
    • Real-time localized sensing and/or imaging of neurotransmitter release and/or uptake in the PNS
    • Quantitative imaging and analysis techniques for PNS and/or organ tissue 
    • Whole-body imaging of neural tracts (in vivo or ex vivo); the ex-vivo approaches may be destructive or non-destructive to the tissue
    • Methods to enhance spatial resolution and/or selectivity for fiber types, fascicles, plexi, or ganglia that do not rely on genetic manipulation or transfer (e.g., methods to ligate an imaging agent, enhance contrast, or selectively activate nerve components without genetic manipulation or transfer)
  • Modeling, simulation, and computation priorities:

NOTE: Applicants to these priorities are strongly encouraged to include verification and validation in their OT1 submission. This may require partnering with existing SPARC investigators.

All simulations and models are expected to interface with the SPARC Data and Resource Center's Modeling and Simulation Core.

  • Adaptation of biomechanical, biochemical, and bioelectrical models of organ function for use in studying the impact of neuromodulation on organ function
  • Computational models to assess safety limits of stimulation and/or blocking of PNS activity (e.g., biophysics and regulatory science for neural interfaces). Models must be validated in vivo
  • Computational models for non-invasive nerve stimulation technologies (e.g., TENS) to provide higher spatial resolution and/or fiber-type specificity. Models must be validated in vivo
  • Interfacing priorities:
    • Adaptation of signals engineering approaches to increase spatial and temporal precision of existing multichannel neuromodulation technologies. For example, applying inverse transform or phased array methods to an existing nerve cuff - Applicants are encouraged to include collaborators with expertise using the specific neuromodulation device and validation in animal models
    • Adaptation and safety testing of existing systems for use in large animal models or humans. Systems should provide high-specificity stimulation and/or recording of the PNS or assess end-organ function. - Must be on a translational pathway towards human use
    • Biosensors to detect end-organ function biomarkers (except for colon, bladder and heart). - Applicants are strongly encouraged to develop their concept in conjunction with a currently funded SPARC investigator
    • Surgical tools to safely find, access, and/or attach interfaces to nerves, fascicles, plexi, and/or ganlgia (e.g., imaging, surgical protocols, etc.) - This Priority only supports development of surgical tooling and methods, not development of new interfaces
    • Methods for performing electrophysiological recordings during MR imaging
    • Enhancement of FDA-cleared or approved non-invasive nerve stimulation technologies (e.g., TENS) to provide higher spatial resolution and/or fiber-type specificity   

Priorities for the February 1, 2018 receipt date (notional) 
Final Priorities will be posted on January 1, 2018 for applications due on February 1, 2018.

  • Tools and services (identified by SPARC1 PIs)
  • Data capture and analysis tools (identified by SPARC4 PIs)
  • Clinical tools (identified by SPARC3 PIs)
  • Some Priorities from the previous receipt date may be included in this list before finalization

RFA-RM-16-003 (previous FOA) 
These Priorities are archived for reference purposes only.

These priorities were posted February 8, 2016.

  • Modification of technologies, such as those previously developed to understand neural circuits in the Central Nervous System, to understand neural circuits in the Peripheral Nervous System; or technology used to understand neural circuits controlling one organ which can be modified for use with another target organ or multiple other organs
  • Sensing techniques for relevant biomarkers to inform closed-loop response systems in organs (e.g., biomolecule sampling/measuring)
  • Technologies for cell-class specific targeting and manipulation in peripheral nerves and ganglia, appropriate for animal models with clinical relevance (e.g., optogenetics)
  • Activity sensors and associated imaging technologies suitable for peripheral nerve and end-organ monitoring (e.g., voltage probes)
  • Reliable, wireless, high density technologies capable of simultaneous recording/stimulation of all neural signals going to and coming from a targeted organ; and or to facilitate functional mapping between multiple organs and nerves
  • Biomimetic or biologically-active interfaces for chronic implants of electrodes and sensors that enhance our ability to chronically study the function of a target organ
  • Invasive and non-invasive technologies for tunable stimulation/inhibition/block of nerve activity (e.g., ultrasound, magnetic fields, etc.)
  • Tools for non-invasive tracing and functional imaging to facilitate minimally invasive surgeries in humans and anatomical mapping
  • Computational platforms and predictive models that generate testable hypotheses of autonomic nervous system control of organs

Previous Priorities for RM-17-009 (current FOA) receipt dates 
These Priorities are archived for reference purposes only.

These priorities were posted March and June, 2017.

  • Imaging and targeting:
    • Quantitative imaging and analysis techniques for PNS and/or organ tissue (including for heart, bladder, and colon)
    • Contrast agents to identify variability due to individual subject differences in either neuroanatomy or neurophysiology
    • Whole-body imaging of neural tracts (in vivo or ex vivo); the ex-vivo approaches may be destructive or non-destructive to the tissue
    • Fascicular tracing/targeting (i.e., methods to increase contrast, biochemical, surgical, and/or viral)
    • Fiber type targeting (i.e., methods to ligate an imaging agent, biochemical, surgical, and/or viral); this includes plexi, unbundled nerves, and/or vascular nerves
    • Methods to assess blood flow within microvasculature of nerves and ganglia. Of particular interest are methods that can observe blood flow under electrodes
    • Non-invasive imaging tools to locate and characterize isolated ganglia and/or nerve branches
    • Organ preparation and/or methods to image neural junctions/terminals in an organ of interest
    • Phantoms to support development of new imaging technologies for neuroanatomy
    • Real-time localized sensing and/or imaging of neurotransmitter release and/or uptake in the PNS
    • Adaptation of stitching, segmenting, and tracing software to PNS and organ datasets
    • Adaptation of biomechanical, biochemical, and bioelectrical models of organ function for use in studying the impact of neuromodulation on organ function
    • Computational models to assess safety limits of stimulation and/or blocking of neural activity (e.g. biophysics and regulatory science for neural interfaces)
    • Biophysical models of electrical neuromodulation that predict selective activation or block specific fiber types and locations. These computational models should be predictive of side effects (i.e. other fibers that may be activated or blocked)
  • Modeling and simulation:
    • Computational models to assess safety limits of stimulation and/or blocking of neural activity (e.g. biophysics and regulatory science for neural interfaces)
    • Computational models of neuromodulation that incorporate variability due to individual subject differences
    • Biophysical models of electrical, infrared, or ultrasonic neuromodulation that predict selective activation or block specific fiber types and locations. These computational models should be predictive of side effects (i.e. other fibers that may be activated or blocked)
    • Adaptation of stitching, segmenting, and tracing software to PNS and organ datasets
    • Adaptation of biomechanical, biochemical, and bioelectrical models of organ function for use in studying the impact of neuromodulation on organ function
  • Surgical:
    • Surgical tools to safely find and/or access nerves, fascicles, and/or ganglia/plexi (e.g. imaging, protocols, etc)
    • Surgical phantoms
    • Real-time in-vivo methods to determine if the PNS is damaged during surgery
    • Methods to repair PNS damage after implant of a neural interface
    • Surgical tools to safely find, access, and/or attach interfaces to nerves, fascicles, and/or ganglia/plexi (e.g. imaging, protocols, etc)
  • Interfacing:
    • New approaches to neuromodulate the PNS that are inherently safe, have high specificity (temporal, spatial, fiber type), and are minimally or non-invasive. 
    • Blocking must be reversible. 
    • Potential approaches might include biologically derived methods to interface with the PNS in vivo, such as artificial biologic constructs, hydrogel-encapsulated cells, or engineered tissue grafts
    • Multi-modal (e.g. optogenetic and electrical) neural interfaces that provide greater specificity than a single-mode interface
    • Adaptation of signals engineering approaches to increase spatial and temporal precision of existing multichannel neuromodulation technologies. For example, applying inverse transform or phased array methods to an existing nerve cuff 
    • Distribution of existing neuromodulation systems to the SPARC consortium. While some adaptation may be required to build interfaces for SPARC1 or SPARC3 investigators, the emphasis of this priority is on the manufacture, distribution, training, and support for these technologies and the associated surgical methods to implant them in nerves, ganglia, or plexi 
    • Adaptation and safety testing of existing systems for use in large animal models or humans. Systems should provide high-specificity neuromodulation of the PNS or assess end-organ function 
    • Biosensors to detect end-organ function biomarkers
    • Methods to identify and understand chronic PNS tissue damage after implant of a neural interface
  • Sample preparation priorities:
    • Transgenic large animal models to facilitate imaging/targeting or interfacing with peripheral nerves and/or end organs
    • Methods for accessing and patch clamping ganglia, plexi, and small nerves. This may include techniques for enzymatic digestion or robotic automation of access to dissociated ganglia
    • Optimization of techniques to label human peripheral nerves and/or end organs. This may include new antibodies, fluorophores, or image processing algorithms to improve immunohistochemical analysis of small nerves or nerve-organ junctions
    • Organ preparation and/or methods to image neural junctions/terminals in an organ of interest
  • Services provided to all SPARC consortium members:
    • Large-scale high-resolution image capture of ex vivo specimens (e.g. TEM, X-ray, or light sheet)
    • Device testing (e.g., mechanical, electrochemical, toxicity, accelerated life, ISO 10993 or equivalent)
    • ASIC design, development, and validation
    • Packaging and encapsulation, or interconnects suitable for >6 month animal trials or human use
    • Genetics services (e.g., RNA-seq, viral vector development, and transgenic line generation)

This page last reviewed on September 1, 2017